[A26-35] Elinzanetant (vasomotor symptoms associated with breast cancer treatment) – Benefit assessment according to §35a Social Code Book V
Last updated 01.07.2026
Project no.:
A26-35
Commission:
Commission awarded on 31.03.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Patients with moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy for breast cancer
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A26-35
| Project no. | Title | Status |
|---|---|---|
| A26-34 | Elinzanetant (vasomotor symptoms in menopause) – Benefit assessment according to §35a Social Code Book V | Commission completed |